Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

13.97 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings. 
Via Benzinga
Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
BLCO Q1 Earnings Call: Misses on Profit, Highlights Product Innovation and Tariff Uncertainty
Eyecare company Bausch + Lomb (NYSE:BLCO) fell short of the market’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year... 
Via StockStory
Topics World Trade
Earnings Scheduled For April 30, 2025
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
From Pomerantz LLP
Via GlobeNewswire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
3 Profitable Stocks Walking a Fine Line
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Economy Supply Chain
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens
From Bausch + Lomb Corporation
Via Business Wire
Why Bausch + Lomb (BLCO) Shares Are Falling Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall Street's... 
Via StockStory
Topics Initial Public Offering
Wednesday's session: gap up and gap down stocks
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Starbucks Posts Weak Earnings, Joins Super Micro Computer, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Bausch + Lomb (NYSE:BLCO) Misses Q1 Sales Targets, Stock Drops 10.4%
Eyecare company Bausch + Lomb (NYSE:BLCO) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
Bausch + Lomb Announces First-Quarter 2025 Results
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know. 
Via StockStory
Topics World Trade
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
From Bausch + Lomb Corporation
Via Business Wire
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move. 
Via StockStory
Topics Bankruptcy
3 of Wall Street’s Favorite Stocks in the Doghouse
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Topics Firearms
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. 
Via StockStory
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and... 
Via StockStory
Why Bausch + Lomb (BLCO) Shares Are Plunging Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Why Bausch + Lomb (BLCO) Stock Is Nosediving
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
From Bausch + Lomb Corporation
Via Business Wire
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.